Next Phase Newsletter

A Venture Capital firm based in the US typically invests between $3-5M initially and $6M to $10M over the lifetime of the investment. Investments are generally in the form of milestone based equity tranches, however the firm also has experience in working with convertible notes.

The firm is currently looking for early stage companies in the Therapeutics, Diagnostics, Medical Device and Healthcare IT spaces. In the Therapeutics space, the firm is opportunistic in terms of subsector but is most interested in indications of Ophthalmology, Cardiovascular, Pulmonary, Anti-Infectives, Metabolic Disorders, Renal Diseases, Oncology, Immunology, Dermatology, and Orphan Diseases. For companies developing therapeutics, the firm is looking for companies primarily with a lead product in preclinical trials, although they will consider companies with products having recently entered Phase I.

In the Medical Device space, the firm strongly prefers that the company at least has an early prototype of their product and the firm is opportunistic in terms of medical device subsector and is open to all classes of device.

In Healthcare IT, the firm is interested in three specific areas: (1) modernizing operations with innovative delivery models, insurance products and clinical trial automation, (2) technology that drive precision in care personalization/targeted therapy and enhanced disease and care management tools, (3) IT empowering patients and caregivers with health education, price/quality transparency, health surveillance and biometric monitoring for enhanced senior care.

For Healthcare IT investments, the firm looks only at post-revenue companies. For drug and device deals, however, the firm only invests in pre-revenue companies and often works with spinouts directly from universities, though this is not a requirement as the firm is open to all types of early stage companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Western Europe is currently investing out of their first fund and looks to invest in early-stage life science companies in the therapeutics space. The firm focuses on Seed investments in the form of equity. Typical allocation is up to $5M for the first ticket. Forty51 Ventures invests in European companies but is open to global opportunities.

The firm is interested in therapeutics, with a focus on oncology, immunology, rare diseases, fibrotic diseases and CNS. The firm will invest in pre-clinical therapeutic companies.

The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. The firm prefers to lead investments and seeks board seat representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm in the US is seeking opportunities in the medical devices, diagnostics, and digital health sectors of life sciences. The firm currently has >$200M AUM and is investing from their second fund. The firm is looking to engage in Seed to Series A financing rounds with initial check sizes between $4-8M. The firm will also make sub $1M investments in some cases, and will consider convertible notes for these checks. The firm will primarily invest in the US, but considers opportunities globally.

The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. The firm is open to all 3 classes of medical devices.

The firm is open to all types of management teams, however clinical experience in the management team is a plus. The firm typically leads or co-leads investments and will seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based growth equity fund is investing out of its latest fund which closed last year. The firm makes equity investments in commercial stage (post regulatory approval) healthcare companies with meaningful revenue and traction. The firm typically invests between $20-60m per company, and focuses on companies in USA and Canada.

The firm invests exclusively in healthcare and is open to all sub-sectors within the industry including products and services. That said, the firm does not invest in pre-revenue companies or those with regulatory risk; investments are made in revenue-generating companies with products that have already received regulatory approval or which do not require regulatory approval. The firm looks for companies with meaningful marketplace validation and growing revenues, where the firm’s investment could help to accelerate the adoption.

The firm prefers to invest in management teams with experience in leading and growing businesses of scale and relevant industry experience.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.